ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer
JO Brett, LM Spring, A Bardia, SA Wander - Breast Cancer Research, 2021 - Springer
In metastatic hormone receptor-positive breast cancer, ESR1 mutations are a common
cause of acquired resistance to the backbone of therapy, estrogen deprivation by aromatase …
cause of acquired resistance to the backbone of therapy, estrogen deprivation by aromatase …
Overcoming endocrine resistance in breast cancer
Estrogen receptor-positive (ER+) breast cancer is the most common breast cancer subtype.
Treatment of ER+ breast cancer comprises interventions that suppress estrogen production …
Treatment of ER+ breast cancer comprises interventions that suppress estrogen production …
Activation of PI3K/AKT/mTOR pathway causes drug resistance in breast cancer
C Dong, J Wu, Y Chen, J Nie, C Chen - Frontiers in pharmacology, 2021 - frontiersin.org
Although chemotherapy, targeted therapy and endocrine therapy decrease rate of disease
recurrence in most breast cancer patients, many patients exhibit acquired resistance …
recurrence in most breast cancer patients, many patients exhibit acquired resistance …
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on …
M Cristofanilli, NC Turner, I Bondarenko, J Ro… - The Lancet …, 2016 - thelancet.com
Background In the PALOMA-3 study, the combination of the CDK4 and CDK6 inhibitor
palbociclib and fulvestrant was associated with significant improvements in progression-free …
palbociclib and fulvestrant was associated with significant improvements in progression-free …
Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a …
J Baselga, SA Im, H Iwata, J Cortés… - The Lancet …, 2017 - thelancet.com
Summary Background Phosphatidylinositol 3-kinase (PI3K) pathway activation is a hallmark
of endocrine therapy-resistant, hormone receptor-positive breast cancer. This phase 3 study …
of endocrine therapy-resistant, hormone receptor-positive breast cancer. This phase 3 study …
Inhibition of the PI3K/AKT/mTOR pathway in solid tumors
PM LoRusso - Journal of clinical oncology, 2016 - ascopubs.org
The phosphoinositide 3-kinase (PI3K) pathway plays an integral role in many cellular
processes and is frequently altered in cancer, contributing to tumor growth and survival …
processes and is frequently altered in cancer, contributing to tumor growth and survival …
Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR …
Background Activation of the PI3K/AKT/mTOR pathway occurs frequently in breast cancer
that is resistant to endocrine therapy. Approved mTOR inhibitors effectively inhibit cell …
that is resistant to endocrine therapy. Approved mTOR inhibitors effectively inhibit cell …
PI3K/AKT/mTOR: role in breast cancer progression, drug resistance, and treatment
A Guerrero-Zotano, IA Mayer, CL Arteaga - Cancer and Metastasis …, 2016 - Springer
Anti-cancer cancer-targeted therapies are designed to exploit a particular vulnerability in the
tumor, which in most cases results from its dependence on an oncogene and/or loss of a …
tumor, which in most cases results from its dependence on an oncogene and/or loss of a …
The present and future of PI3K inhibitors for cancer therapy
Abstract Phosphoinositide 3-kinase (PI3K) signaling regulates cellular proliferation, survival
and metabolism, and its aberrant activation is one of the most frequent oncogenic events …
and metabolism, and its aberrant activation is one of the most frequent oncogenic events …
Mechanisms of aromatase inhibitor resistance
CX Ma, T Reinert, I Chmielewska, MJ Ellis - Nature Reviews Cancer, 2015 - nature.com
Abstract Oestrogen receptor-positive (ER+) breast cancer is a major cause of cancer death
in women. Although aromatase inhibitors suppress the function of ER and reduce the risk of …
in women. Although aromatase inhibitors suppress the function of ER and reduce the risk of …